Regulus Therapeutics Inc

-0.04 (-9.39%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)37.23M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.01 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$0.52
50-Day MA$0.69
200-Day MA$1.06
See more pivots

Regulus Therapeutics Inc Stock, NASDAQ:RGLS

4224 Campus Point Court, Suite 210, San Diego, California 92121
United States of America
Phone: +1.858.202.6300
Number of Employees: 24


Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.